A new study found a high prevalence of chronic kidney disease (CKD) among people with systemic lupus erythematosus (SLE), ...

Systemic Lupus Erythematosus is an autoimmune disease affecting multiple organs. Symptoms include rashes, joint pain, anemia, ...

A recent dual-cohort study has found that Lupus Low Disease Activity State (LLDAS) is an attainable and effective treatment ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

The Global Systemic Lupus Erythematosus Treatment Market is valued approximately at USD 2.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.64% over the forecast ...

Which of the statements about the 2025 guideline summary for the treatment of systemic lupus erythematosus are correct?

Patients with systemic lupus erythematosus with a history of cutaneous lupus erythematosus are more likely to have high ...

DelveInsight's CD40/CD40L Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Participants who are enrolled will be given a dose of ADI-001, followed by a 28-day dose-limiting toxicity window.

Hydroxychloroquine exposure during the first trimester of pregnancy was associated with a lower risk for preeclampsia among women with SLE.

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.